Programme
Sunday, October 4
13:00-13:30
Opening
Jan Konvalinka (Director of IOCB Prague),
Milan Pospíšil (Rector of UCT Prague),
Linda Štucbartová (Vice President, Czech-Israeli Chamber)
13:30-14:10
Zdeněk Hostomský (IOCB Prague, Czech Republic)
Development of PARP inhibitors – A case study
14:10-14:50
Valery Krizhanovsky (Weizmann Institute of Science, Rehovot, Israel)
Senescent cells: where to find them and how to deal with them
14:50-15:20
Coffee break
15:20-16:00
Miklos Bekes (Arvinas Inc., New Haven, Connecticut, United States)
PROTAC targeted protein degraders – the future is now
16:00-16:40
Haim Barr (Weizmann Institute of Science, Rehovot, Israel)
The role of diversified platforms in academic drug discovery
16:40-17:20
Poster session + refreshments
19:00
Social evening
Monday, October 5
09:00-09:40
Neta Regev-Rudzki (Weizmann Institute of Science, Rehovot, Israel)
Cell-communication in malaria: the parasite’s social media network
09:40-10:20
Stephan Bachmann (F. Hoffmann-La Roche Ltd., Basel, Switzerland)
Scale-Up of Organometallic Flow Chemistry – A Highly Atroposelective Negishi Coupling Enables the Commercial Manufacturing Process of Divarasib
10:20-10:50
Coffee break
10:50-11:30
Gabriela Koifman (Weizmann Institute of Science, Rehovot, Israel)
Gene Amplification Evolution as a Mechanism of Cancer Adaptation and Drug Resistance in Patient-Derived Organoids
11:30-12:10
Katarína Pšenáková (PharmTheon, Czech Republic)
Beyond the Bench – Building Therapies That Matter
12:10-12:50
Yosef Yarden (Weizmann Institute of Science, Rehovot, Israel)
Mechanisms of resistance to anti-cancer kinase inhibitors
12:50-14:10
Lunch
14:10-14:50
Chris Meier (University of Hamburg, Department of Chemistry, Institute of Organic Chemistry, Germany)
Enzyme- or photocleavable masking for the intracellular delivery of bioactive highly phosphorylated nucleotides
14:50-15:30
Eliane Hadas Yardeni (Weizmann Institute of Science, Rehovot, Israel)
GPCRs through the Ligand Lens: Exploring Dopamine Receptor Pharmacology
15:30-16:10
Luke Piggott (Debiopharm, Lausanne, Switzerland)
Potholes in the Pipeline: Navigating the Realities of Oncology R&D
16:10-16:50
Poster session + refreshments
16:50-18:00
Excursions: UCT Brewery, IOCB labs
Tuesday, October 6
09:00-09:40
Filip Doušek (Theorema AI, Czech Republic)
Causal disease modelling
09:40-10:20
Donna Matzov (Weizmann Institute of Science, Rehovot, Israel)
Single-Particle Cryo-EM in GPCR Drug Discovery: Methodology and Case Studies
10:20-10:50
Coffee break
10:50-11:30
Irena Adkins (VRG Therapeutics, Budapest, Hungary)
Drug Development: From Target Validation to First-in-Human Studies
11:30-12:10
Menachem Rubinstein (Weizmann Institute of Science, Rehovot, Israel)
Bispecific VSV-G Engagers: A Platform for Targeted in vivo Gene Delivery
12:10-12:50
David Stibal / Roberto F. Alvarez (i&I Prague, Czech Republic)
Technology transfer system of IOCB – how to build a start-up
12:50-14:10
Lunch
14:10-14:50
Shea Johnson (AbbVie, Ludwigshafen, Germany)
Discovery and Development VYALEVTM for Treatment of Advanced Parkinson’s Disease
14:50-15:00
Closing, best poster award
